Epsilogen

Ypsilon Therapeutics

The company develops T-cell receptor mimic antibodies and bispecific T-cell engagers to treat patients with solid tumours, such as triple-negative breast and lung cancer.

Cytospire Therapeutics

This company develops multispecific immune cell engager antibodies for cancer patients to enhance and direct immune system activity against solid tumours.

Nectin Therapeutics

This company develops novel immunotherapeutic antibodies and antibody-drug conjugates for patients with solid and haematological cancers.

Tacalyx

This company develops antibody-based therapeutics targeting tumour associated carbohydrate antigens for the treatment of solid tumours in cancer patients.

Alyssum Therapeutics

This company develops B cell-based targeted immunotherapies for patients with solid tumours and complex immunological conditions.

Emergence Therapeutics

This biopharmaceutical company develops antibody-drug conjugate immunotherapies to treat solid tumours for patients with high unmet medical needs.

Arch Oncology

This biotechnology firm develops antibody therapies to treat patients with solid tumours and hematologic malignancies.

Pheon Therapeutics

The company develops antibody-drug conjugates to treat solid tumours for the healthcare and pharmaceutical sectors.